Titanium 4 L5This page contains information on Titanium 4 L5 for veterinary use.
The information provided typically includes the following:
- Titanium 4 L5 Indications
- Warnings and cautions for Titanium 4 L5
- Direction and dosage information for Titanium 4 L5
Titanium 4 L5This treatment applies to the following species:
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza3 Vaccine
Modified Live Virus
Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin
from the Signature cell line®
Infectious Bovine Rhinotracheitis Virus (IBR), Modified Live Virus
Bovine Virus Diarrhea Virus (BVD), Modified Live Virus
Bovine Parainfluenza3 Virus (PI3), Modified Live Virus
Titanium® 4 L5 contains desiccated Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza3 Vaccine and a bacterin diluent (Lepto 5). Titanium® 4 L5 is a multiantigenic modified live vaccine to be used as an aid in the prevention of disease caused by infectious bovine rhinotracheitis virus (IBR), bovine virus diarrhea virus (BVD), bovine parainfluenza3 virus (PI3), and a bacterin to aid in the prevention of disease caused by Leptospira canicola, Leptospira grippotyphosa, Leptospira hardjo, Leptospira icterohaemorrhagiae, and Leptospira pomona.
The four viral antigens are combined in the proper ratio, stabilized and desiccated into one cake. The desiccated viral fractions are rehydrated for use with a specially processed liquid Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin, Lepto 5.
Serologic surveys indicate the four viruses are widespread in the cattle population. The viruses are considered contributors to the respiratory disease complex of cattle. Multiple infections do occur, and secondary bacterial infections may exacerbate the disease signs.
Infectious Bovine Rhinotracheitis Virus
IBR is an acute upper respiratory disease. Signs of IBR may include elevated temperature, hyperpnea, dyspnea, excessive nasal and ocular discharge, rapid breathing, cough and depression. Reproductive problems including abortions have been observed.
Bovine Virus Diarrhea Virus
BVD is often obscured or confused with other conditions of the respiratory disease complex. Clinical signs may include fever, anorexia, coughing, depression, diarrhea, and occasional lameness. BVD may be inapparent, chronic, or a fatal mucosal disease. BVD may cause suppression of the immune system. Affected animals have increased susceptibility to secondary infections. BVD in pregnant animals may cause abortions or malformed and weak calves at birth. Chronic disease with erosions in the alimentary tract is referred to as “Mucosal Disease” and is usually fatal.
Bovine Parainfluenza3 Virus
Parainfluenza3 infections may cause few noticeable signs. Disease signs caused by PI3 virus generally appear within 14 days after shipment and arrival of calves at their destination. Signs are weakness, depression, watery to mucopurulent nasal discharge, fever, coughing, and weight loss. PI3 is a contributor to the Bovine Respiratory Disease Complex. Antibodies are present in over 80% of young calves.
Leptospirosis is widespread in the animal population of the United States and is considered one of the most infectious diseases of farm animals.
Man can become infected either from animals with the disease or from an infective environmental source. In animals, the disease is known to cause reproduction disorders, loss of weight, decreased milk production and sometimes death. The economic losses suffered are very large. The disease can be caused by several specific leptospires.
Five important serovars have been identified and are included in this product. Because specific serovar diagnosis is very difficult, and also due to the widespread nature of potential infection, it is recommended that all animals be vaccinated before introduction into the concentrated holding areas currently utilized on many premises. When infection is diagnosed, it is advisable to separate those animals showing disease signs and to vaccinate the remainder of the herd with Lepto 5 alone. The apparent effectiveness of Lepto 5 will depend upon the number of animals exposed and incubating the disease at the time of vaccination. Vaccination cannot be expected to protect animals already in the incubating stages of the disease.
Serologic studies indicate widespread distribution of all of these causative agents.
Efficacy was demonstrated by vaccination and challenge studies. Following vaccination, seroconversion occurred in 81% of the calves receiving a single vaccination, and 100% after 2nd vaccination. Following challenge, vaccinated animals exhibited significant reduction of morbidity and clinical signs. In contrast, unvaccinated challenged calves exhibited clinical signs of extended duration, increased severity and extended virus shedding.
Research demonstrated Titanium® 4 L5 is safe and efficacious; however, individual animals may be unable to develop an adequate immune response following vaccination due to: concurrent disease, malnutrition, parasitism, or stress due to shipment or environmental conditions.
Safety in pregnant heifers and cows was demonstrated in trials conducted at three separate sites. The heifers and cows were vaccinated prior to breeding with Titanium® 5 L5 HB followed by a post-breeding vaccination at the first, second or third trimester of pregnancy. The cows were observed from pregnancy vaccination through calving for fetal loss. Heifers and cows vaccinated with Titanium® 5 L5 HB had abortions and calving rates similar to the control cows.
Calving Rates (normal calves delivered/total deliveries)
The fetal loss in the two groups was similar with 3.43% in the Titanium® 5 L5 HB vaccinated groups and 4.65% in the control groups. Following calving, each calf’s health was monitored for 4 weeks. The health of the calves in the Titanium® 5 L5 HB vaccinated dams was similar to the health of calves born to the control dams. WARNING: Fetal health risks associated with vaccination of pregnant animals with modified live vaccines cannot be unequivocally determined by clinical trials conducted for licensure. Vaccination of pregnant animals with modified live vaccines should be discussed with a veterinarian.
INDICATIONS FOR USE:
Titanium® 4 L5 contains BVD Type I and BVD Type II and is recommended for the vaccination of healthy cows and heifers, no less than 30 days prior to breeding, as an aid in the prevention of disease caused by infectious bovine rhinotracheitis virus (IBR), bovine virus diarrhea virus, Type I (BVD), bovine virus diarrhea virus, Type II (BVD), bovine parainfluenza3 virus (PI3), and Leptospira canicola, Leptospira grippotyphosa, Leptospira hardjo, Leptospira icterohaemorrhagiae, and Leptospira pomona. Titanium® 4 L5 may be administered to pregnant cattle provided they were vaccinated, according to label directions, with Titanium® 3, Titanium® 4 L5, Titanium® 5 or Titanium® 5 L5 HB 30 to 60 days prior to breeding. Titanium® 4 L5 may also be administered to calves nursing pregnant cows provided their dams were vaccinated as described above.
Dosage and Administration
Rehydrate the desiccated vial with accompanying diluent and shake well. Inject 2 mL subcutaneously using aseptic technique, followed by a second dose of monovalent bovine respiratory syncytial virus vaccine (Titanium® BRSV) to be given 14 to 28 days after the first dose. Annual revaccination is recommended. Calves vaccinated before weaning should be revaccinated 30 days after weaning when the possible influence of maternal antibodies is decreased.
Recommended for the vaccination of healthy cows and heifers no less than 30 days prior to breeding. Titanium® 3, Titanium® 4 L5, Titanium® 5 or Titanium® 5 L5 HB can also be administered to pregnant cattle provided they were vaccinated, according to label directions, with Titanium® 3, Titanium® 4 L5, Titanium® 5 or Titanium® 5 L5 HB 30 to 60 days prior to breeding. Failure to follow label directions may result in abortions. The Titanium line may be administered to calves nursing pregnant cows provided their dams were vaccinated as described above. Store at 35° to 46° F (2° to 8° C). DO NOT FREEZE. Use entire contents when first opened. Allergic reactions may follow the use of vaccines. ANTIDOTE: Epinephrine. Do not vaccinate within 21 days before slaughter. Burn container and all unused contents. Contains thimerosal as a preservative.
FOR USE IN ANIMALS ONLY
50 dose (100 mL)
20 per case
Manufactured by: Diamond Animal Health, Inc., Des Moines, Iowa 50327 U.S.A.
U.S. Veterinary License No. 213
Distributed by: Elanco Animal Health, Greenfield, IN 46140 U.S.A., A Division of Eli Lilly and Company
NAC No.: 1031058.0
A Division of Eli Lilly & Co.
2500 INNOVATION WAY, GREENFIELD, IN, 46140
|Small Animal Product Customer Service:||888-545-5973|
|Every effort has been made to ensure the accuracy of the Titanium 4 L5 information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.|
Copyright © 2015 North American Compendiums. Updated: 2015-09-25